Handelsavisen
prelaunch
Companies ›Healthcare ›046210.KQ
04
046210.KQ — KOSDAQ Biotechnology & Medical Research

046210.Kq

$1 480,00
Open in Charts → Attach watcher ⌖
— —
USD
Set alert
Last 30 days
1D5D1M3M6MYTD1Y5YMax
Live price chart loads from the market-data widget.
Mcap
—
P/E
—
EV / Rev
—
Div yield
—
Op margin
-52,2 %
ROE
-4,3 %
Net margin
-20,8 %
Debt / equity
0,22
Beta
—
52w range
—
Volume
—
Day range
—
Prev close
—
Open
—
Next earnings
—
Ex-dividend
—
TR 1Y
—
About

The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.

Business. The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.

Classification92 %
SectorHealthcare
Business sectorPharmaceuticals & Medical Research
IndustryBiotechnology & Medical Research
ActivityPharmaceuticals & Medical Research
Generated · model-assisted
Sell-side consensus
—consensus pending
— buy— hold— sell
Avg 12m price target—
Upcoming events
— missing data
See all catalysts →

At a glance

Score
—
not yet scored
Valuation
—
valuation pending
Analysts
—
not yet wired
Ownership
—
not yet wired
Profitability→
-4,3 %
return on equity
Quality
—
not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

0
  • No recent newsroom coverage mentioning 046210.

    • Sector rotation

    Sector1D1Mvs mkt
    Materials+2,3 %+6,6 %+1,7 %
    Communication Services+2,2 %−5,5 %+1,6 %
    Energy+0,6 %+3,3 %+0,0 %
    Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %
    Information Technology+0,6 %+6,7 %+0,0 %
    Consumer Discretionary+0,4 %+7,6 %−0,2 %
    Financials−0,3 %−2,8 %−0,9 %
    Consumer Staples−0,4 %+2,5 %−1,0 %
    Real Estate−0,7 %+10,9 %−1,3 %
    Industrials−1,9 %−3,1 %−2,5 %
    Utilities−1,9 %+28,2 %−2,5 %

    Developing storylines

    No tracked sagas currently linked to 046210.KQ. Browse all sagas →

    Analysis

    AI analysis
    Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

    Opportunity

    — missing data

    Upcoming catalysts

    Scheduled public events. Informational only — not investment advice.

    • Macro
    • Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
    • Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
    • Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
    • Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
    • Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
    • Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
    • Macro & political
    • ElectionSE Swedish Election2026-09-14 · SE
    • ElectionUS U.S. Midterms2026-11-03 · US
    • ElectionFR French Legislative2027-06-01 · FR

    Pre-earnings brief

    — missing data

    Signals & dispatch

    peak dispatch · —

    Composite-score breakdown

    Synthesis

    Business

    The company operates in the biotechnology and medical research sector, focusing on pharmaceuticals and medical research, and generates revenue primarily through the development and commercialization of biotechnology products.

    Classification92 %
    SectorHealthcare
    Business sectorPharmaceuticals & Medical Research
    IndustryBiotechnology & Medical Research
    ActivityPharmaceuticals & Medical Research
    AI synthesis
    GENERATED

    The company's capital structure is characterized by a low debt-to-equity ratio of 0.22, indicating a relatively conservative approach to financing. The company maintains a strong liquidity position with a current ratio of 2.26, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's operating cash flow is negative at -640,631,280 KRW, and its free cash flow is also negative at -3,338,588,050 KRW, indicating that it is not generating positive cash from operations.

    In terms of profitability, the company is currently unprofitable, with a net loss of 3,125,849,750 KRW and an operating loss of 7,848,707,350 KRW. The return on equity is -4.32%, and the return on assets is -3.36%, both of which are below the industry median for biotechnology companies. The company's gross profit margin is 59.6%, which is in line with the industry median.

    The company's revenue is concentrated in a single segment, as disclosed in its financial statements, with no significant geographic diversification reported. This concentration may expose the company to higher risk if the segment or region experiences a downturn.

    The company's growth trajectory is currently negative, with a net loss and a decline in operating income. The outlook for the current fiscal year does not indicate a significant improvement in revenue or profitability. The company's capital expenditures are negative, indicating a reduction in investment in long-term assets.

    The company's risk assessment indicates a low level of liquidity and dilution risk. There are no immediate filing-based liquidity or dilution flags, and the company has not issued new shares recently. The company's financial position is supported by a strong equity base and a low debt load, which reduces the risk of financial distress.

    Recent events, as disclosed in the company's filings, do not indicate any significant changes in the company's financial position or strategic direction. The company has not announced any major acquisitions, partnerships, or product launches that would significantly impact its financial performance.

    Key takeaways
    • The company has a strong liquidity position with a current ratio of 2.26.
    • The company is currently unprofitable, with a net loss and a negative return on equity.
    • The company's revenue is concentrated in a single segment, which may increase its exposure to market risks.
    • The company has a low debt-to-equity ratio, indicating a conservative capital structure.
    • The company's operating cash flow and free cash flow are negative, suggesting it is not generating positive cash from operations.

    Bull / Bear case

    analysis pipeline
    — missing data

    In focus — financials by report

    Valuation

    Market price
    $1 480,00
    Market cap
    —
    Enterprise valueⓘ
    —
    P/Eⓘ
    —
    Non-GAAP P/Eⓘ
    —
    EV / Revenueⓘ
    —
    EV / Op incomeⓘ
    —
    EV / OCFⓘ
    —
    P / Bⓘ
    —
    P / Tangible bookⓘ
    —
    Tangible book
    $72.35B
    Net cashⓘ
    $14.16B
    Current ratioⓘ
    2.3
    Debt / equityⓘ
    0.2
    ROAⓘ
    -3.4%
    ROEⓘ
    -4.3%
    Cash conversionⓘ
    20.0%
    CapEx / revenueⓘ
    -12.6%
    SBC / revenueⓘ
    —
    Dilution ratioⓘ
    0.0%

    Revenue by segment

    Market share

    — missing data

    Business relationships

    — missing data

    Supply chain

    — missing data

    Peer comparison

    — missing data

    Market position

    Stress test

    — missing data

    Predictor forecast

    Options

    — missing data

    Short squeeze

    — missing data

    Earnings-call key lines

    — missing data

    Estimate revisions

    consensus EPS · 26-week trend
    — missing data

    Sell-side observations

    — missing data

    Themes

    — missing data

    ESG

    — missing data

    Risk factors

    Dilution riskLow
    Liquidity riskLow
    Filing-based flags
    • No immediate filing-based liquidity or dilution flags were detected.

    Benchmarks vs cohort

    Op Margin-52,1 %Above median
    Net Margin-20,8 %Above median
    ROE-4,3 %Above median
    Capex / Rev-12,6 %Below median
    D/E0,22Bottom quartile
    Cash Conv0,20Bottom quartile

    Corporate actions / M&A

    — missing data

    FX exposure

    — missing data

    Comparable transactions

    — missing data

    Derivatives & instruments

    — missing data

    Actions

    Ask Handelsavisen

    — missing data
    Data sources
    • Market data
    • Market data cache
    • Issuer disclosures
    • Public news
    • Earnings transcripts
    • Consensus estimates
    • ESG data
    How metrics are computed
    • Dilution Ratio
      (shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
    • Net Cash
      cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
    • Capex To Revenue
      capital_expenditure / revenue
    • Return On Equity
      net_income / total_equity
    • Debt To Equity
      (short_term_debt + long_term_debt) / total_equity
    • Cash Conversion Ratio
      operating_cash_flow / net_income
    Source documents
    • 046210.KQ Market data — financials · 2026-05-26

    Ownership & reference

    Insider activity

    — missing data

    Short positioning

    — missing data

    Geographic breakdown

    — missing data
    Listings · one canonical issuer all listings resolve to the canonical
    046210.KQCanonical
    KOSDAQ · USD

    Intel & risk

    peak dispatch · —
    OSINT findings
    Dilution riskLow
    Liquidity riskLow
    No immediate filing-based liquidity or dilution flags were detected.

    Evidence & claims

    From filings & derived data
    — missing data

    The Thread

    Everything we know, in order
    — missing data
    Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage